SEQUANA MEDICAL NV (SEQUA.BR) Stock Price & Overview

EBR:SEQUA • BE0974340722

Current stock price

0.505 EUR
+0.03 (+5.54%)
Last:

The current stock price of SEQUA.BR is 0.505 EUR. Today SEQUA.BR is up by 5.54%. In the past month the price decreased by -9.17%. In the past year, price decreased by -55.7%.

SEQUA.BR Key Statistics

52-Week Range0.463 - 1.738
Current SEQUA.BR stock price positioned within its 52-week range.
1-Month Range0.463 - 0.65
Current SEQUA.BR stock price positioned within its 1-month range.
Market Cap
37.638M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.24
Dividend Yield
N/A

SEQUA.BR Stock Performance

Today
+5.54%
1 Week
-2.32%
1 Month
-9.17%
3 Months
-31.48%
Longer-term
6 Months -47.72%
1 Year -55.70%
2 Years -66.45%
3 Years -89.71%
5 Years -93.99%
10 Years N/A

SEQUA.BR Stock Chart

SEQUANA MEDICAL NV / SEQUA Daily stock chart

SEQUA.BR Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to SEQUA.BR. When comparing the yearly performance of all stocks, SEQUA.BR is a bad performer in the overall market: 97.19% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

SEQUA.BR Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to SEQUA.BR. SEQUA.BR has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SEQUA.BR Earnings

Next Earnings DateMar 25, 2026
Last Earnings DateN/A
PeriodQ2 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

SEQUA.BR Forecast & Estimates

10 analysts have analysed SEQUA.BR and the average price target is 2.79 EUR. This implies a price increase of 452.07% is expected in the next year compared to the current price of 0.505.

For the next year, analysts expect an EPS growth of 81.63% and a revenue growth 782.35% for SEQUA.BR


Analysts
Analysts84
Price Target2.79 (452.48%)
EPS Next Y81.63%
Revenue Next Year782.35%

SEQUA.BR Groups

Sector & Classification

Index Membership

SEQUA.BR Financial Highlights

Over the last trailing twelve months SEQUA.BR reported a non-GAAP Earnings per Share(EPS) of -1.24. The EPS decreased by -32.31% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-51.85M
Industry RankSector Rank
PM (TTM) N/A
ROA -355.86%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-12.99%
Sales Q2Q%-100%
EPS 1Y (TTM)-32.31%
Revenue 1Y (TTM)-100%

SEQUA.BR Ownership

Ownership
Inst Owners32.97%
Shares74.53M
Float55.58M
Ins Owners4.4%
Short Float %N/A
Short RatioN/A

About SEQUA.BR

Company Profile

SEQUA logo image Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 48 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.

Company Info

IPO: 2019-02-11

SEQUANA MEDICAL NV

Kortrijksesteenweg 1112, Sint-Denijs-Westrem

Ghent OOST-VLAANDEREN BE

Employees: 48

SEQUA Company Website

SEQUA Investor Relations

Phone: 3292928065.0

SEQUANA MEDICAL NV / SEQUA.BR FAQ

What does SEQUA do?

Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 48 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.


What is the current price of SEQUA stock?

The current stock price of SEQUA.BR is 0.505 EUR. The price increased by 5.54% in the last trading session.


Does SEQUANA MEDICAL NV pay dividends?

SEQUA.BR does not pay a dividend.


How is the ChartMill rating for SEQUANA MEDICAL NV?

SEQUA.BR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


Can you provide the PE ratio for SEQUA stock?

SEQUANA MEDICAL NV (SEQUA.BR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.24).


What is the market capitalization of SEQUA stock?

SEQUANA MEDICAL NV (SEQUA.BR) has a market capitalization of 37.64M EUR. This makes SEQUA.BR a Nano Cap stock.


What is the ownership structure of SEQUANA MEDICAL NV (SEQUA.BR)?

You can find the ownership structure of SEQUANA MEDICAL NV (SEQUA.BR) on the Ownership tab.